Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
The material change disclosed is a transaction involving a connected person:
- Dr. S. Dexter, a connected person of Dr. P. J. T. Vallance (a Person Discharging Managerial Responsibilities), purchased 7,655 Ordinary Shares of GSK.
- Transaction Date: September 17, 2015.
- Price: 1,299.50 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share purchase described above.
Investor Verification Checklist
- Verify the total shareholding of Dr. S. Dexter post-transaction to assess concentration of interest.
- Confirm the relationship and potential influence of Dr. P. J. T. Vallance as a Person Discharging Managerial Responsibilities.
- Check the prevailing market price of GSK shares on September 17, 2015, to compare against the purchase price of 1,299.50 pence.